Patents by Inventor Donald J. P. Pinto

Donald J. P. Pinto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thrombin or factor Xa inhibitors
    Patent number: 6500855
    Abstract: This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
    Type: Grant
    Filed: January 2, 2002
    Date of Patent: December 31, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Patrick Y. S. Lam, Charles G. Clark, Renhau Li, Donald J. P. Pinto
  • Heteroaryl- phenyl heterobicyclic factor Xa inhibitors
    Publication number: 20020119986
    Abstract: The present application describes heteroaryl-phenyl heterobicycles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
    Type: Application
    Filed: June 22, 2001
    Publication date: August 29, 2002
    Inventors: Donald J.P. Pinto, Mimi L. Quan, Francis J. Woerner, Renhua Li
  • Thrombin or factor Xa inhibitors
    Publication number: 20020115854
    Abstract: This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
    Type: Application
    Filed: December 4, 2001
    Publication date: August 22, 2002
    Inventors: Patrick Y.S. Lam, Charles G. Clark, John M. Fevig, Robert A. Galemmo, Qi Han, Irina C. Jacobson, Renhau Li, Donald J.P. Pinto, Ruth R. Wexler
  • Disubstituted pyrazolines and triazolines as factor Xa inhibitors
    Patent number: 6436985
    Abstract: The present application describes disubstituted pyrazolines and triazolines of formulae I and II: or pharmaceutically acceptable salt forms thereof, wherein one of M1 and M2 maybe N and D may be a variety of N-containing groups, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: December 1, 2000
    Date of Patent: August 20, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Donald J. P. Pinto
  • Heteroaryl-phenyl substituted factor Xa inhibitors
    Publication number: 20020103202
    Abstract: The present application describes heteroaryl-phenyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of factor Xa.
    Type: Application
    Filed: June 22, 2001
    Publication date: August 1, 2002
    Inventors: Donald J.P. Pinto, Mimi L. Quan, Francis J. Woerner
  • Nitrogen containing heterobicycles as factor Xa inhibitors
    Patent number: 6413980
    Abstract: The present application describes nitrogen containing heterobicyclics and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: July 2, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: John M. Fevig, Joseph Cacciola, Charles G. Clark, Qi Han, Patrick Yuk Sun Lam, Donald J.P. Pinto, James R. Pruitt, Mimi L. Quan, Karen A. Rossi
  • Cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds as factor Xa inhibitors
    Patent number: 6407256
    Abstract: The present application describes inhibitors of factor Xa which are cyano-pyrazole, cyano-triazole, cyano-imidazole, and cyano-pyrrole compounds of Formulae Ia, Ib, Ic, and Id: or pharmaceutically acceptable salt forms thereof.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: June 18, 2002
    Inventor: Donald J. P. Pinto
  • Thrombin or factor Xa inhibitors
    Patent number: 6403583
    Abstract: This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: June 11, 2002
    Inventors: Patrick Y. S. Lam, Charles G. Clark, John M. Fevig, Robert A. Galemmo, Qi Han, Irina C. Jacobson, Renhau Li, Donald J. P. Pinto, Ruth R. Wexler
  • Inhibitors of factor Xa with a neutral P1 specificity group
    Patent number: 6403620
    Abstract: The present application describes inhibitors of factor Xa with a neutral P1 specificity group of formula I: or pharmaceutically acceptable salt forms thereof, wherein R and E may be groups such as methoxy and halo.
    Type: Grant
    Filed: September 10, 1999
    Date of Patent: June 11, 2002
    Inventors: Robert A. Galemmo, Jr., Celia Dominguez, John M. Fevig, Qi Han, Patrick Y. Lam, Donald J. P. Pinto, James R. Pruitt, Mimi L. Quan
  • Thrombin or factor Xa inhibitors
    Patent number: 6369227
    Abstract: This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: April 9, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Patrick Y. S. Lam, Charles G. Clark, Renhau Li, Donald J. P. Pinto
  • Thrombin or factor Xa inhibitors
    Publication number: 20020022614
    Abstract: This invention relates generally to heteroaryl-phenyl substituted compounds that are inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
    Type: Application
    Filed: June 29, 2001
    Publication date: February 21, 2002
    Inventors: Donald J.P. Pinto, Mimi L. Quan
  • Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors
    Publication number: 20020016326
    Abstract: The present application describes nitrogen containing heteroaromatics with ortho-substituted P1's and derivatives thereof of formula I: 1
    Type: Application
    Filed: April 12, 2001
    Publication date: February 7, 2002
    Inventors: Robert A. Galemmo, Lori L. Bostrom, Donald J.P. Pinto, Karen A. Rossi
  • Guanidine mimics as factor Xa inhibitors
    Patent number: 6339099
    Abstract: The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D—E represent guanidine mimics, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: June 18, 1998
    Date of Patent: January 15, 2002
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Patrick Y. Lam, Charles G. Clark, Celia Dominguez, John M. Fevig, Qi Han, Renhua Li, Donald J. P. Pinto, James R. Pruitt, Mimi L. Quan
  • Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
    Patent number: 6271237
    Abstract: The present application describes nitrogen containing heteroaromatics with ortho-substituted P1's and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D is substituted ortho to G on E and may be CH2NH2, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: August 7, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Robert A. Galemmo, Jr., Lori L. Bostrom, Donald J. P. Pinto, Karen A. Rossi
  • Disubstituted pyrazolines and triazolines as factor Xa inhibitors
    Patent number: 6191159
    Abstract: The present application describes disubstituted pyrazolines and triazolines of formulae I and II: or pharmaceutically acceptable salt forms thereof, wherein one of M1 and M2 maybe N and D may be a variety of N-containing groups, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: February 20, 2001
    Assignee: Dupont Pharmaceuticals Company
    Inventor: Donald J. P. Pinto
  • Inhibitors of factor Xa with a neutral P1 specificity group
    Patent number: 5998424
    Abstract: The present application describes inhibitors of factor Xa with a neutral P1 specificity group of formula I: ##STR1## or pharmaceutically acceptable salt forms thereof, wherein R and E may be groups such as methoxy and halo.
    Type: Grant
    Filed: June 18, 1998
    Date of Patent: December 7, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Robert A. Galemmo, Jr., Celia Dominguez, John M. Fevig, Qi Han, Patrick Y. Lam, Donald J. P. Pinto, James R. Pruitt, Mimi L. Quan
  • Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
    Patent number: 5939418
    Abstract: Isoxazolines, isothiazolines and pyrazolines which are inhibitors of Factor Xa, pharmaceutical compositions containing these compounds, and methods of using these compounds as anticoagulant agents for treatment and prevention of thromboembolic disorders. The compounds can be represented by the formula: ##STR1## where X is O, S or NR.sup.15.
    Type: Grant
    Filed: December 17, 1996
    Date of Patent: August 17, 1999
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Mimi Lifen Quan, John Wityak, Robert Anthony Galemmo, Jr., Petrus F. W. Stouten, James Russell Pruitt, Donald J. P. Pinto
  • Prostaglandin synthase inhibitors
    Patent number: 5593994
    Abstract: This invention relates to ortho substituted phenyl compounds as inhibitors of prostaglandin synthase, to pharmaceutical compositions comprising such compounds and to methods of using such compounds as antiinflammatory and antipyretic agents.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: January 14, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Douglas G. Batt, Donald J. P. Pinto, Michael J. Orwat, Joseph J. Petraitis, William J. Pitts
  • Substituted naphthofurans as anti-inflammatory agents
    Patent number: 5244917
    Abstract: This invention relates to substituted naphthofurans as anti-inflammatory and anti-allergic agents, pharmaceutical compositions containing them, processes for their preparation, and their use as anti-inflammatory and anti-allergic agents. The naphthofurans are of the formula ##STR1## and pharmaceutically acceptable salts thereof wherein: R.sup.1 is CN or COOR.sup.9 ;R.sup.2 and R.sup.8 independently are H, C.sub.1 -C.sub.4 alkyl, COR.sup.9 or COR.sup.10 ;R.sup.3, R.sup.4, R.sup.6 and R.sup.7 are independently H, C.sub.1 -C.sub.4 alkyl, halogen, phenyl, CF.sub.3 or OR.sup.9 ;R.sup.5 is H, C.sub.1 -C.sub.4 alkyl, or COR.sup.9 ; andR.sup.9 and R.sup.10 are independently C.sub.1 -C.sub.4 alkyl, halogen or aryl.
    Type: Grant
    Filed: June 2, 1992
    Date of Patent: September 14, 1993
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Joseph J. Petraitis, Donald J. P. Pinto